AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
AstraZeneca PLCNYSE: AZN
Deferred Tax Liabilities · Q3 FY2026 · quarter ended Sep 2026
Deferred tax liabilities broadly unchanged from a year ago
Deferred tax liabilities stood at $3.61B at the end of Q3 FY2026, up 0.2% from a year earlier and up 4.4% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Deferred tax liabilities amounted to 3.0% of total assets at the end of Q3 FY2026, down 0.1 pp from a year earlier.
- Deferred tax liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred tax liabilities keeps rising in the next quarterly balance sheet after a +0.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.51B USD
- Year-over-year change
- +6.1%
- 4-year CAGR
- -13.3%
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.51B | +6.1% |
| FY2024 | 2024-12-31 | 3.31B | +10561.3% |
| FY2023 | 2023-12-31 | 31M | -98.9% |
| FY2022 | 2022-12-31 | 2.94B | -52.6% |
| FY2021 | 2021-12-31 | 6.21B | — |
Deferred Tax Liabilities vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.2% is the 3rd highest of 9, against a peer median of -10.5%.
- Deferred tax liabilities amounts to 3.0% of total assets for AZN, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.46B USD | — | — | 3.8% | |
| Jun 2026 | $5.29B USD | +128.0% | +44.0% | 4.3% | |
| Sep 2026 | $4.84B USD | -19.3% | +19.4% | 2.4% | |
| Jun 2026 | DKK 4.27B DKK | -56.4% | -2.2% | 0.7% | |
| Sep 2026 | $3.61B USD | +0.2% | +6.0% | 3.0% | |
| Jun 2026 | $2.28B USD | -10.8% | -2.9% | 1.7% | |
| Jun 2026 | $1.96B USD | -20.8% | +32.9% | 1.0% | |
| Jun 2026 | $1.43B USD | +0.4% | -7.1% | 1.1% | |
| Jun 2026 | $1.3B USD | -6.1% | +398.9% | 1.4% | |
| Jun 2026 | $222M USD | -10.1% | -53.2% | 0.3% | |
| Peer median (excluding AZN) | — | -10.5% | +8.6% | 1.4% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.33B | 6.17B | 5.84B | 5.49B | 5.71B |
| Short-term Investments | 69M | 77M | 20M | 37M | 30M |
| Net Receivables | 8.13B | 9.19B | 8.41B | 11.24B | 15.18B |
| Inventory | 8.98B | 4.7B | 5.42B | 5.29B | 6.56B |
| Other Current Assets | 1.22B | 1.13B | 3.75B | 2.04B | 1.25B |
| Total Current Assets | 26.24B | 22.59B | 25.05B | 25.83B | 28.72B |
| Property, Plant & Equipment (Net) | 10.17B | 9.45B | 10.5B | 11.65B | 14.7B |
| Goodwill | 20B | 19.82B | 20.05B | 21.03B | 21.24B |
| Intangible Assets | 42.39B | 39.31B | 38.09B | 37.18B | 37.85B |
| Long-term Investments | 0 | 0 | 1.78B | 0 | 2.53B |
| Tax Assets | 4.33B | 3.26B | 0 | 5.35B | 0 |
| Other Non-current Assets | 2.23B | 2.05B | 5.65B | 3.01B | 9.04B |
| Total Non-current Assets | 79.12B | 73.89B | 76.07B | 78.21B | 85.35B |
| Total Assets | 105.36B | 96.48B | 101.12B | 104.04B | 114.07B |
| Account Payables | 2.82B | 2.55B | 3.27B | 3.64B | 25.28B |
| Short-term Debt | 1.57B | 5.23B | 5.13B | 2.16B | 3.19B |
| Tax Payables | 1.38B | 1.36B | 2.08B | 1.81B | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 14.94B | 15B | 6.13B | 17.31B | 686M |
| Total Current Liabilities | 22.59B | 26.29B | 30.54B | 27.87B | 30.62B |
| Long-term Debt | 28.13B | 22.97B | 22.37B | 26.51B | 24.72B |
| Deferred Tax Liabilities | 6.21B | 2.94B | 31M | 3.31B | 3.51B |
| Deferred Revenue (Non-current) | 26M | 14M | 7M | 0 | 0 |
| Other Non-current Liabilities | 8.36B | 6.48B | 8.15B | 4.37B | 5.1B |
| Total Non-current Liabilities | 43.48B | 33.13B | 31.41B | 35.3B | 34.74B |
| Total Liabilities | 66.08B | 59.43B | 61.95B | 63.16B | 65.36B |
| Common Stock | 387M | 387M | 388M | 388M | 388M |
| Retained Earnings | 1.71B | (574M) | 4.52B | 3.16B | 10.97B |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 1.89B | 1.92B | (1.9B) | 1.86B | 2.04B |
| Minority Interest | 19M | 21M | 23M | 85M | 52M |
| Total Equity | 39.29B | 37.06B | 39.17B | 40.87B | 48.72B |
| Total Debt | 30.69B | 29.14B | 28.62B | 30.11B | 29.7B |
| Net Debt | 24.36B | 22.98B | 22.78B | 24.63B | 23.99B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.